Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 98

    1.

    Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms.

    Goldin LR, Björkholm M, Kristinsson SY, Samuelsson J, Landgren O.

    Genome Med. 2009 May 29;1(5):55.

    PMID:
    19490586
    [PubMed]
    Free PMC Article
    2.

    A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

    Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL.

    Nat Genet. 2009 Apr;41(4):455-9. Epub 2009 Mar 15.

    PMID:
    19287384
    [PubMed - indexed for MEDLINE]
    3.

    The C allele of the JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

    Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.

    BMC Med Genet. 2012 Jan 17;13(1):6. [Epub ahead of print]

    PMID:
    22251709
    [PubMed - as supplied by publisher]
    Free Article
    4.

    JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.

    Oh ST, Gotlib J.

    Expert Rev Hematol. 2010 Jun;3(3):323-37. Review.

    PMID:
    21082983
    [PubMed - indexed for MEDLINE]
    5.

    The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.

    Zhang SJ, Qiu HX, Li JY, Shi JY, Xu W.

    Int J Lab Hematol. 2010 Aug 1;32(4):381-6. Epub 2010 Mar 23.

    PMID:
    20331763
    [PubMed - indexed for MEDLINE]
    6.

    JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.

    Ma W, Kantarjian H, Zhang X, Wang X, Zhang Z, Yeh CH, O'Brien S, Giles F, Bruey JM, Albitar M.

    PLoS One. 2010 Aug 13;5(8):e12165.

    PMID:
    20730051
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    7.

    Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.

    Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, Park MR, Chi HS, Kim HY, Kim HJ, Lee MH, Kim H, Won JH, Yoon HJ, Oh DY, Nam EM, Bae SH, Kim BK; Korean MPN Working Party.

    Thromb Haemost. 2009 Mar;101(3):547-51.

    PMID:
    19277418
    [PubMed - indexed for MEDLINE]
    8.

    JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

    Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, Elena C, Boveri E, Pascutto C, Lazzarino M, Cazzola M.

    Cancer. 2006 Nov 1;107(9):2206-11.

    PMID:
    16998940
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis.

    Smalberg JH, Koehler E, Darwish Murad S, Plessier A, Seijo S, Trebicka J, Primignani M, de Maat MP, Garcia-Pagan JC, Valla DC, Janssen HL, Leebeek FW; European Network for Vascular Disorders of the Liver (EN-Vie).

    Blood. 2011 Apr 14;117(15):3968-73. Epub 2011 Mar 1.

    PMID:
    21364191
    [PubMed - indexed for MEDLINE]
    10.

    Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

    Baran-Marszak F, Magdoud H, Desterke C, Alvarado A, Roger C, Harel S, Mazoyer E, Cassinat B, Chevret S, Tonetti C, Giraudier S, Fenaux P, Cymbalista F, Varin-Blank N, Le Bousse-Kerdilès MC, Kiladjian JJ, Velazquez L.

    Blood. 2010 Dec 23;116(26):5961-71. Epub 2010 Sep 24.

    PMID:
    20870899
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.

    Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, Dirnhofer S, Tichelli A, Tzankov A.

    Br J Haematol. 2009 Jul;146(2):150-7. Epub 2009 May 19.

    PMID:
    19466975
    [PubMed - indexed for MEDLINE]
    12.

    The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.

    Trifa AP, Cucuianu A, Petrov L, Urian L, Militaru MS, Dima D, Pop IV, Popp RA.

    Ann Hematol. 2010 Oct;89(10):979-83. Epub 2010 Apr 27.

    PMID:
    20422415
    [PubMed - indexed for MEDLINE]
    13.

    Mechanisms of mutations in myeloproliferative neoplasms.

    Levine RL.

    Best Pract Res Clin Haematol. 2009 Dec;22(4):489-94. Review.

    PMID:
    19959098
    [PubMed - indexed for MEDLINE]
    14.

    Molecular characterization of chronic myeloproliferative neoplasias in México.

    Ruiz-Argüelles GJ, Garcés-Eisele J, Ortiz-López R, Rivas-Llamas R, Gómez-Almaguer D, Ruiz-Delgado GJ.

    Hematology. 2009 Oct;14(5):261-5.

    PMID:
    19843380
    [PubMed - indexed for MEDLINE]
    15.

    JAK2V617F mutations in myeloid malignancies: single center experience.

    Panovska-Stavridis I, Cevreska L, Ivanovski M, Stojanovik A, Lozance M, Matevska N, Dimovski A, Serafimoski V.

    Prilozi. 2008 Dec;29(2):257-67.

    PMID:
    19259051
    [PubMed - indexed for MEDLINE]
    16.

    Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms.

    Teofili L, Martini M, Iachininoto MG, Capodimonti S, Nuzzolo ER, Torti L, Cenci T, Larocca LM, Leone G.

    Blood. 2011 Mar 3;117(9):2700-7. Epub 2011 Jan 6.

    PMID:
    21212285
    [PubMed - indexed for MEDLINE]
    17.

    TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

    Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, Druker BJ, Bagby GC, Deininger MW.

    Blood. 2011 Dec 8;118(24):6392-8. Epub 2011 Aug 22.

    PMID:
    21860020
    [PubMed - in process]
    Free PMC Article
    18.

    JAK and MPL mutations in myeloid malignancies.

    Tefferi A.

    Leuk Lymphoma. 2008 Mar;49(3):388-97. Review.

    PMID:
    18297515
    [PubMed - indexed for MEDLINE]
    19.

    Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.

    Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC.

    Blood. 2010 Mar 11;115(10):2003-7. Epub 2010 Jan 8.

    PMID:
    20061559
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    A gain-of-function mutation of JAK2 in myeloproliferative disorders.

    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.

    N Engl J Med. 2005 Apr 28;352(17):1779-90.

    PMID:
    15858187
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk